

Calliditas Therapeutics - Upping Probability of Positive Data-Readout

Redeye considers the upcoming results of Calliditas Therapeutic's phase III trial as one of the highlights on the Scandinavian biotech scene this autumn. After going through the literature and speaking to KOLs in the field, we raise the likelihood of approval to 70% (65%), leading to a new Base case of SEK 160 (140). We see upside potential of some +100% on the back of positive results.

[Read more and download the Research Update](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Calliditas Therapeutics - Upping Probability of Positive Data-Readout](#)